Teduglutide

Native GLP-2 is released from intestinal L-cells after a meal but is destroyed by DPP-4 within about seven minutes. Teduglutide substitutes glycine for alanine at position 2, blocking that cleavage and extending the half-life roughly twentyfold. Acting through the GLP-2 receptor on subepithelial myofibroblasts and enteric neurons, it triggers release of IGF-1, KGF and other mediators that drive crypt cell proliferation, increase villus height, slow gastric emptying and transit, and increase mesenteric blood flow. The net result in short bowel syndrome is measurably more fluid and nutrient absorption, which is why the primary endpoint in its trials is litres of parenteral support avoided per week.

Targets: GLP-2 receptor, Intestinal subepithelial myofibroblasts, IGF-1 / KGF downstream signalling

• · The actual label dose is 0.05 mg/kg once daily — 3.5 mg for a 70 kg adult. The range shown covers roughly 40-90 kg. Halve to 0.025 mg/kg in moderate-to-severe renal impairment or end-stage renal disease.

Work out your exact syringe units →

• very commonAbdominal pain and distension— Affects a large minority of patients, particularly in the first weeks as the bowel adapts.
• very commonNausea and vomiting
• very commonInjection-site reactions— Rotate sites; this is a daily injection for life.
• commonStoma complications — swelling, obstruction of the stoma opening— The stoma itself grows. Stoma appliances often need resizing.
• commonColorectal polyps— A direct consequence of the growth signal. Colonoscopy is mandatory before starting and periodically thereafter.
• commonFluid overload, oedema, congestive heart failure— Because absorption improves, parenteral fluid must be actively reduced or the patient goes into fluid overload.
• uncommonBiliary and pancreatic disease — cholecystitis, cholangitis, pancreatitis— Labelled warning; requires lab and imaging surveillance.
• rareAccelerated neoplastic growth— The theoretical risk that the growth signal drives an existing malignancy. This is the reason for the malignancy screening requirement.

• Active gastrointestinal malignancy — the drug is a potent intestinal growth factor and this is an absolute contraindication.
• Active non-gastrointestinal malignancy requires the drug to be stopped or weighed very carefully.
• A colonoscopy with removal of polyps is required before starting; skipping it is not optional.

• redundantapraglutide — Same receptor, same mechanism — never combine GLP-2 analogues.
• redundantglepaglutide — Same receptor; combining adds risk without benefit.
• cautionoral-medications — By increasing absorptive surface and slowing transit, teduglutide can raise absorption of oral drugs including benzodiazepines and psychotropics; doses may need reducing.

• · Colonoscopy or alternative imaging before initiation, at 1 year, then at least every 5 years while on treatment.
• · Bilirubin, alkaline phosphatase, lipase and amylase at baseline and every 6 months.
• · Fluid and electrolyte status at every visit — this is the most common real-world problem, and parenteral support must be actively weaned.
• · Stoma output volume and appliance fit for ostomy patients.

FDA-approved (Gattex) and EMA-approved (Revestive) for short bowel syndrome in adults and paediatric patients 1 year and older who are dependent on parenteral support. Prescription-only specialty biologic.

• Gattex (teduglutide) US prescribing information, Takeda (label)
• Jeppesen et al. 2012, STEPS phase 3 trial of teduglutide in short bowel syndrome, Gastroenterology (trial)
• Schwartz et al., STEPS-2/STEPS-3 long-term extension data (trial)

The critical thing to understand about teduglutide is that it does not act on enterocytes. The GLP-2 receptor is not expressed on the absorptive cells that ultimately do the work — it sits on subepithelial myofibroblasts, enteric neurons and enteroendocrine cells. Receptor activation on those cells triggers release of paracrine mediators, principally IGF-1 and keratinocyte growth factor, and it is those mediators that drive crypt cell proliferation in the neighbouring epithelium. This is an indirect trophic mechanism operating one cell layer removed from its target. That architecture explains several clinical features that otherwise look odd. It explains why the effect builds over weeks rather than hours — you are growing tissue, not switching on a transporter. It explains why benefit reverses on discontinuation, because villus hypertrophy regresses once the growth signal stops. It explains why the intestinotrophic effect vastly outlasts a two-hour plasma half-life. And it explains the polyp risk and the malignancy contraindication honestly: you are administering a daily proliferative signal to the entire intestinal epithelium, including any dysplastic clone already present. The secondary effects matter clinically as much as the villus growth. GLP-2 receptor activation on enteric neurons slows gastric emptying and small bowel transit, which increases contact time with whatever absorptive surface exists — in a patient with 60 cm of jejunum, transit time is often the binding constraint rather than surface area. It also increases mesenteric blood flow. And it reduces gastric acid secretion. The net absorptive gain in short bowel syndrome is the sum of more surface, slower transit, better perfusion and less acid load, not villus height alone. The practical corollary that catches people out: improved absorption is not the endpoint. If parenteral fluid is not actively reduced as absorption improves, the patient goes into fluid overload. Teduglutide creates the capacity for weaning; the weaning has to be done deliberately.

The single most common real-world failure is fluid overload, and it is not a drug toxicity — it is a management failure. Absorption improves, the parenteral prescription stays the same, and the patient accumulates fluid until they present with oedema or decompensated heart failure. The fix is to treat parenteral volume as something that must be actively reduced on a schedule, not something that gets adjusted when a problem appears. The second is skipping the baseline colonoscopy. It is required, it is not optional, and the reason is that you are about to give a daily growth signal to any dysplastic tissue that is already there. The third is stoma complications in ostomy patients, which surprise people. The stoma itself hypertrophies along with the rest of the bowel. Appliances stop fitting, the aperture becomes obstructive, and this frequently gets misread as an obstruction elsewhere. Resize the appliance. The fourth is abdominal pain and distension in the first weeks, which is very common and mostly self-limiting as the bowel adapts — but it is also exactly what early obstruction looks like, so it cannot simply be assumed benign. The fifth is reconstitution error. This is a single-use, preservative-free product: 0.5 mL of sterile water into the 5 mg vial, let it stand 30 seconds, roll between the palms for 15 seconds, do not shake, use within 3 hours, discard the remainder. People coming from the peptide world try to make a 5 mg vial last a week. It will not, and there is nothing in it to stop bacterial growth.

1. 3.5 mgDay 1 onward — There is no dose titration. Full weight-based dose from the first injection: 0.05 mg/kg once daily, which is 3.5 mg for a 70 kg adult. The figure shown here is that 70 kg dose.
2. 1.75 mgDay 1 onward, renal impairment — 0.025 mg/kg once daily — half dose — in moderate to severe renal impairment or end-stage renal disease. This is because clearance approximates GFR, so a failing kidney directly raises exposure.
3. —From week 4 — The real ladder on this drug is downward, and it is the parenteral support volume that descends, not the peptide dose. Reassess fluid balance every 4 weeks and cut parenteral volume by 10-20% at a time, guided by urine output, weight and electrolytes. Failing to wean is what produces the oedema and heart failure on the label.
4. —Week 20-24 — The pivotal endpoints were assessed at weeks 20 and 24. If parenteral volume has not fallen by 20% by then, the patient is a non-responder and continuing indefinitely is hard to justify against the cost and the polyp surveillance burden.

• GLP-2 receptor (GLP2R), human — pEC50 10.7 (EC50 approximately 2 x 10^-11 M, i.e. 20 pM) in a cAMP accumulation assay in HEK293 cells stably expressing hGLP-2R, per the IUPHAR/BPS Guide to Pharmacology.

  Gs-coupled agonism raising cAMP in subepithelial myofibroblasts, enteric neurons and enteroendocrine cells. Highly selective — it does not meaningfully engage GLP-1 or glucagon receptors.

• IGF-1 (downstream paracrine mediator) — Not a direct target.

  Released by GLP-2R-bearing myofibroblasts and acts on adjacent crypt cells to drive proliferation. IGF-1 signalling is required for the intestinotrophic effect in knockout models — this is the actual effector arm.

• Keratinocyte growth factor (KGF/FGF7) — Not a direct target.

  Second paracrine mediator contributing to epithelial proliferation and crypt depth.

• Enteric neurons (GLP-2R-expressing) — Same receptor.

  Slowed gastric emptying and small bowel transit, increased mesenteric blood flow, reduced gastric acid secretion. In a very short bowel, the transit effect may contribute as much absorptive benefit as the mucosal growth.

• STEPS — Teduglutide reduces need for parenteral support among patients with short bowel syndrome (NCT00798967) Phase 3 · n=86 · 24 weeks · 2012

  Responders, defined as patients achieving a greater than 20% reduction in weekly parenteral support volume from baseline at both weeks 20 and 24. Result: 27/43 (63%) on teduglutide 0.05 mg/kg/day versus 13/43 (30%) on placebo, P = .002.

Nothing happens in the first days beyond side effects. Mucosal adaptation is a tissue-growth process. Citrulline and villus changes begin over 2-4 weeks. Measurable reductions in parenteral support volume typically appear by week 12, and the pivotal endpoints were assessed at weeks 20 and 24. Full adaptation continues for months, and the long-term extension data show continued weaning in some patients out to two and three years. If nothing has moved at 24 weeks, it is not going to.

Never combine teduglutide with apraglutide or glepaglutide. Same receptor, same mechanism, additive proliferative signal and additive polyp risk with no additional benefit. These are substitutions, not additions. The interaction that actually matters clinically is with oral medication. Teduglutide increases absorptive surface and slows transit, so oral drugs that were previously poorly absorbed in a short bowel suddenly are absorbed. The label calls this out specifically for benzodiazepines and psychotropics. If a patient with 80 cm of small bowel has been on a stable dose of an oral drug for years, that dose was calibrated to a malabsorbing gut. Watch for unexpected sedation, and reduce doses proactively rather than reactively. Same logic applies to oral anticoagulants, immunosuppressants and antiepileptics where a level can be measured — check levels in the first month. Do not run a GLP-1 agonist alongside without a specific reason. GLP-1 slows gastric emptying too, and in a short bowel patient the combined transit effect can tip into obstruction-like symptoms.

Teduglutide is the reference standard for GLP-2 therapy and the only one with a label. Its weakness is the schedule: a daily subcutaneous injection, reconstituted from a lyophilised vial, for life. That is a meaningful burden for a patient already spending twelve hours a night connected to a pump. Apraglutide (weekly) and glepaglutide (twice weekly, ready-to-use autoinjector) both exist to solve that burden, and both hit their phase 3 primary endpoints — and both received regulatory pushback rather than approval. So as of now the more convenient options are not available and teduglutide remains the only choice. On efficacy, cross-trial comparison is unreliable because the endpoints differ: STEPS used a responder definition of greater than 20% reduction at weeks 20 and 24, apraglutide's STARS used relative percentage change in weekly volume at week 24, and glepaglutide's EASE-1 used absolute change in weekly volume. Anybody ranking these three on efficacy is comparing different measurements. Against no GLP-2 therapy at all, the alternatives in short bowel syndrome are dietary optimisation, antisecretory therapy, antimotility agents and, at the far end, intestinal transplantation. Teduglutide sits meaningfully between medical management and transplant.

A specialty biologic dispensed through limited-distribution pharmacy, priced in the region of hundreds of thousands of dollars per year, with the exact figure varying by weight-based dose and payer contract. I did not verify a current price in this session and will not quote an invented one. In practice essentially nobody pays cash; access runs through payer authorisation and manufacturer support programmes.

• ?Protein binding is not stated in the Gattex label and I did not resolve a figure elsewhere, so it is null.
• ?Volume of distribution is given in the label as 103 mL/kg; the 7.2 L here is that figure scaled to a 70 kg adult, which is arithmetic rather than a directly measured population value.
• ?Tmax is given as a range of 3 to 5 hours in the label; 4 is the midpoint, not a measured median.
• ?Time to steady state is not stated in the label and cannot be inferred cleanly, since the drug does not accumulate and its clinical effect is driven by tissue growth rather than plasma steady state.
• ?STEPS-2 and STEPS-3 long-term extension data are real and widely cited, but I did not resolve specific PMIDs for them in this session, so they are not listed as verified trials here.
• ?Plasma citrulline as a response biomarker is well established in the intestinal failure literature but is not a labelled monitoring parameter, and assay availability varies widely.
• ?The paediatric indication (patients 1 year and older) is real but its trial data are not covered here.

• Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure Jeppesen PB, Pertkiewicz M, Messing B, et al., Gastroenterology, 2012 · PMID 22982184

  The pivotal STEPS phase 3 trial that produced the FDA approval. 63% versus 30% responder rate at weeks 20 and 24.

• GATTEX (teduglutide) for injection, US prescribing information Takeda Pharmaceuticals America, Inc., DailyMed / FDA label

  Source for every pharmacokinetic number here: 88% bioavailability, Tmax 3-5 h, Vd 103 mL/kg, clearance 123 mL/hr/kg, t-half 2 h healthy and 1.3 h in SBS, no accumulation on repeat dosing. Also the source for the 33-residue sequence, the 3752 Da molecular weight, and the colonoscopy and laboratory surveillance schedule.

• Identification of Pappalysin-2 (PAPP-A2), a modulator of the IGF-1 pathway, as a potential marker of teduglutide efficacy in patients with short bowel syndrome de Dreuille B, et al., Clinical Nutrition, 2025 · PMID 40414050

  Recent work on why some patients respond and others do not, via the IGF-1 arm — directly relevant to the non-responder problem.

• Teduglutide, IUPHAR/BPS Guide to Pharmacology ligand 7049 — GLP-2 receptor pEC50 10.7 IUPHAR/BPS Guide to Pharmacology

  Source for the receptor affinity: EC50 20 pM at the human GLP-2 receptor, cAMP accumulation assay in HEK293 cells.